This video examines second-line treatment options for non-muscle invasive bladder cancer patients who relapse after BCG therapy and are not eligible for radical cystectomy.
About 50% to 60% of patients with high-risk stage I bladder cancers relapse after treatment with Bacillus Calmette–GuÃ©rin (BCG) therapy. The standard of care for these patients is radical cystectomy, though due to comorbidities some patients cannot undergo this type of surgery.
In this video, James M. McKiernan, MD, of Columbia University Medical Center in New York, discusses second-line treatment options for BCG-refractory bladder cancer patients who are not eligible for radical cystectomy.
Related Content:Bladder Cancer